These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 23178652

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL.
    Oncogene; 2010 Nov 25; 29(47):6257-66. PubMed ID: 20729919
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug 25; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 5. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
    Chao TT, Wang CY, Lai CC, Chen YL, Tsai YT, Chen PT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    J Pharmacol Exp Ther; 2014 Nov 25; 351(2):352-8. PubMed ID: 25187431
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL.
    J Hepatol; 2010 Jan 15; 52(1):88-95. PubMed ID: 19913321
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY, Huang TT, Chen YT, Chen JL, Chu PY, Huang CT, Wang WL, Lau KY, Dai MS, Shiau CW, Tseng LM.
    EBioMedicine; 2019 Feb 15; 40():263-275. PubMed ID: 30651219
    [Abstract] [Full Text] [Related]

  • 12. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.
    Breast Cancer Res; 2012 Apr 26; 14(2):R68. PubMed ID: 22537901
    [Abstract] [Full Text] [Related]

  • 13. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
    Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ, Chen KF.
    Oncotarget; 2015 Feb 10; 6(4):2164-79. PubMed ID: 25537503
    [Abstract] [Full Text] [Related]

  • 14. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
    Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL, Chen KF.
    PLoS One; 2013 Feb 10; 8(2):e55705. PubMed ID: 23383345
    [Abstract] [Full Text] [Related]

  • 15. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
    Liu CY, Huang TT, Huang CT, Hu MH, Wang DS, Wang WL, Tsai WC, Lee CH, Lau KY, Yang HP, Chen MH, Shiau CW, Tseng LM, Chen KF.
    Eur J Cancer; 2017 Feb 10; 72():112-123. PubMed ID: 28027514
    [Abstract] [Full Text] [Related]

  • 16. Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
    Liu L, Huang Z, Chen J, Wang J, Wang S.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):142. PubMed ID: 29986744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.
    Mol Cancer Ther; 2012 Feb 09; 11(2):452-63. PubMed ID: 22180308
    [Abstract] [Full Text] [Related]

  • 20. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q, Qin S, Yuan X, Zhang L, Ji J, Liu X, Ma W, Zhang Y, Liu P, Sun Z, Zhang J, Liu Y.
    Oncol Rep; 2017 Jul 09; 38(1):598-606. PubMed ID: 28560452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.